Remepy

Biotechnology ResearchNew York, United States51-200 Employees

Remepy is Pioneering Hybrid Drugs™. 
Many medical conditions are better treated by combining pharmaceutical and non-pharmaceutical treatments. Hybrid drugs are a new type of drug asset, that combines traditional drugs with proprietary treatment protocols delivered measured and adapted using our AI capabilities. 
Remepy’s Digital Molecules™ are designed to be the software apps within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug and are constantly measured and tracked and personalized using advanced AI capabilities. 
The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. We also address physical, motor, psychological, and behavioral symptoms

Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine  Remepy’s Digital Molecule™ and traditional drug components.

Sign up for free to view info

Email Format Employee directory